Key facts
- NeuroLutions’s last known valuation is $88.5M (Mar 2025).
- It has raised $59.9M; the latest was Merger/Acquisition in Apr 2025.
- Status: Acquired/Merged.
- ·Watchlist + deal alerts for NeuroLutions
- ·The full record, as it builds
Funding rounds
No funding rounds for NeuroLutions are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NeuroLutions
Developer of neurorehabilitation devices designed to help stroke survivors restore lost arm function non-invasively. The company's devices use non-invasive electroencephalography electrodes, instead of an implanted electrode or other invasive methods for brain-computer interface therapy, the EEG data is then wirelessly conveyed to a tablet for analysis of the intended muscle movement, enabling patients to facilitate muscle re-education and maintain or increase range of motion.
- Sector
- Healthcare
- HQ
- Saint Louis, MO, United States
- Founded
- 2007
- Employees
- 37
- Website
- neurolutions.com/
- Ownership
- Acquired/Merged
NeuroLutions doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NeuroLutions shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NeuroLutions in its N-PORT filings yet. We sweep new filings monthly.